Use of Exparel for Postoperative Analgesia Following Bariatric Surgery

• Status: Unknown status
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the efficacy of liposomal bupivicaine in post operative analgesia for patients undergoing bariatric surgery when compared to conventional local analgesia. Patients will be randomly selected to receive either liposomal bupivicaine or conventional bupivicaine via a transversus abdominal plane block during surgery. Patients will be followed post-operatively to assess use of narcotics, post-operative pain and nausea scores, and length of stay.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McMaster University
• Collaborator: Pacira Pharmaceuticals, Inc
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• The patient previously met NIH criteria for bariatric surgery and has not received a previous bariatric surgical procedure

• The patient is aged 18-65 years and has completed the screening and preparation process prescribed by the Ontario Bariatric Network

Exclusion Criteria:

• Inability to give informed consent

• ASA > 4

• Planned procedure other than Roux-en-Y gastric bypass (RYGB) or contraindications to RYGB

• BMI > 55 kg/m2

• Revisional procedure

• Allergies or suspected allergies to local anesthetic medications (bupivicaine)

• Renal insufficiency (GFR < 30ml/min)

• History of chronic pain needing daily medications for the last >3 months